Company / SG&A Expense
Gain Therapeutics, Inc. SG&A Expense History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$10.8M
FY2024
5-year range
$1.2M / $10.8M
FY2021-FY2024
Trend
+13.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 3 consecutive years, from $1M in FY2021 to $11M in FY2024.
Based on SEC 10-K filings.
$11M in FY2024 with a 3-year CAGR of +105.2%.
Increased from $7M to $11M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +105.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 3-year CAGR of +105.2%, indicating consistent growth.
- In FY2024, sg&a expense increased 13.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $10.8M | +13.1% |
| FY2023 | $9.5M | +39.7% |
| FY2022 | $6.8M | +446.5% |
| FY2021 | $1.2M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026